Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

Leuci V, Casucci GM, Grignani G, Rotolo R, Rossotti U, Vigna E, Gammaitoni L, Mesiano G, Fiorino E, Donini C, Pisacane A, Ambrosio LD, Pignochino Y, Aglietta M, Bondanza A, Sangiolo D.

Oncoimmunology. 2018 Feb 15;7(5):e1423167. doi: 10.1080/2162402X.2017.1423167. eCollection 2018.

2.

BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.

Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, Macagno M, Leuci V, Rotolo R, Donini C, Basiricò M, Quaglino P, Fierro MT, Giordano S, Sibilia M, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2018 Jul 15;24(14):3377-3385. doi: 10.1158/1078-0432.CCR-17-1914. Epub 2018 Apr 12.

PMID:
29650750
3.

Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.

Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, Senetta R, Cangemi M, Cattaneo G, Martin V, Coha V, Gallo S, Pignochino Y, Sapino A, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2017 May 1;23(9):2277-2288. doi: 10.1158/1078-0432.CCR-16-1524. Epub 2016 Nov 4.

4.

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.

Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D.

J Transl Med. 2016 May 5;14(1):119. doi: 10.1186/s12967-016-0872-2.

5.

Adoptive immunotherapy against sarcomas.

Mesiano G, Leuci V, Giraudo L, Gammaitoni L, Carnevale Schianca F, Cangemi M, Rotolo R, Capellero S, Pignochino Y, Grignani G, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2015 Apr;15(4):517-28. doi: 10.1517/14712598.2015.987121. Epub 2014 Dec 16. Review.

PMID:
25516119
6.

Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective.

Gammaitoni L, Leuci V, Mesiano G, Giraudo L, Todorovic M, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2014 Sep;14(9):1259-70. doi: 10.1517/14712598.2014.918099. Epub 2014 May 16. Review.

7.

Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.

Leuci V, Mesiano G, Gammaitoni L, Aglietta M, Sangiolo D.

Curr Gene Ther. 2014 Feb;14(1):52-62. Review.

8.

Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.

Sangiolo D, Mesiano G, Gammaitoni L, Leuci V, Todorovic M, Giraudo L, Cammarata C, Dell'Aglio C, D'Ambrosio L, Pisacane A, Sarotto I, Miano S, Ferrero I, Carnevale-Schianca F, Pignochino Y, Sassi F, Bertotti A, Piacibello W, Fagioli F, Aglietta M, Grignani G.

Cancer Res. 2014 Jan 1;74(1):119-29. doi: 10.1158/0008-5472.CAN-13-1559. Epub 2013 Dec 19.

9.

Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.

Leuci V, Mesiano G, Gammaitoni L, Todorovic M, Giraudo L, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Anticancer Agents Med Chem. 2014 Feb;14(2):211-22. Review.

10.

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.

Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S, Caravelli D, Giacone E, Venesio T, Balsamo A, Pignochino Y, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2013 Aug 15;19(16):4347-58. doi: 10.1158/1078-0432.CCR-13-0061. Epub 2013 Jun 21.

11.

Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers.

Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, Jordaney N, Carnevale-Schianca F, Gallo S, Fagioli F, Piacibello W, Elia AR, Pignochino Y, Dell'aglio C, Grignani G, Cignetti A, Aglietta M, Sangiolo D.

J Immunother. 2012 Sep;35(7):579-86.

PMID:
22892454
12.

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.

Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2012 Jun;12(6):673-84. doi: 10.1517/14712598.2012.675323. Epub 2012 Apr 14. Review.

PMID:
22500889
13.

Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors.

Leuci V, Mesiano G, Gammaitoni L, Cammarata C, Capellero S, Todorovic M, Jordaney N, Circosta P, Elia A, Lesnikova M, Georges GE, Piacibello W, Fagioli F, Cignetti A, Aglietta M, Sangiolo D.

J Biotechnol. 2011 Dec 10;156(3):218-26. doi: 10.1016/j.jbiotec.2011.09.001. Epub 2011 Sep 10.

PMID:
21933686
14.

Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks.

Sangiolo D, Leuci V, Gallo S, Aglietta M, Piacibello W.

Expert Opin Biol Ther. 2011 May;11(5):655-66. doi: 10.1517/14712598.2011.565325. Epub 2011 Mar 7. Review.

PMID:
21375466
15.

Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich syndrome gene.

Leuci V, Gammaitoni L, Capellero S, Sangiolo D, Mesuraca M, Bond HM, Migliardi G, Cammarata C, Aglietta M, Morrone G, Piacibello W.

Stem Cells. 2009 Nov;27(11):2815-23. doi: 10.1002/stem.224.

16.

Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectors.

Tesio M, Gammaitoni L, Gunetti M, Leuci V, Pignochino Y, Jordaney N, Capellero S, Cammarata C, Caione L, Migliaretti G, Fagioli F, Tabilio A, Aglietta M, Piacibello W.

Stem Cells. 2008 Jun;26(6):1620-7. doi: 10.1634/stemcells.2008-0161. Epub 2008 Mar 27.

Supplemental Content

Support Center